Emerging therapies for atopic dermatitis: TRPV1 antagonists
Emerging therapies for atopic dermatitis: TRPV1 antagonists
复制标题
DOI：
10.1016/j.jaad.2017.12.023
复制
发表时间：
2018-03-01
影响因子：
13.8
通讯作者：
Swerlick, Robert A.
中科院分区：
文献类型：
--
作者：
Bonchak, Jonathan G.;Swerlick, Robert A.
瞬时受体电位(Trp)离子通道是全身躯体感觉信号的重要介体。在过去的十年里，我们对TRPs在多种皮肤生理过程中的作用的理解有了很大的增长。Trp阳离子通道V亚家族成员1(TRPV1)是这个离子通道大家族中被理解较好的成员之一，它影响涉及瘙痒的多个通路。此外，TRPV1似乎在维持皮肤屏障功能方面发挥作用。总而言之，这些特性使TRPV1成为特应性皮炎新疗法的成熟靶点。神经激肽拮抗剂可能会影响类似的通路，并已对此进行了研究。早期试验数据表明，这些疗法是安全的，但对特应性皮炎的疗效评估仍有待评估，因为我们正在等待II和III期临床试验数据的公布。(J am Acad Dermatol 2018；78：S63-6.)
Transient receptor potential (TRP) ion channels are important mediators of somatosensory signaling throughout the body. Our understanding of the contribution of TRPs to a multitude of cutaneous physiologic processes has grown substantially in the past decade. TRP cation channel subfamily V member 1 (TRPV1), one of the better-understood members of this large family of ion channels, affects multiple pathways involved in pruritus. Further, TRPV1 appears to play a role in maintaining skin barrier function. Together, these properties make TRPV1 a ripe target for new therapies in atopic dermatitis. Neurokinin antagonists may affect similar pathways and have been studied to this effect. Early trials data suggest that these therapies are safe, but assessment of their efficacy in atopic dermatitis is pending as we await publication of phase II and III clinical trials data. (J Am Acad Dermatol 2018; 78: S63-6.)